Bristol's Advanced Melanoma Candidate Outperforms Standard Chemo in Trial
Tuesday, November 18, 2014
Source: Yahoo News
A study found that 40% of melanoma patients taking Bristol-Myers Squibb's immunotherapy drug Opdivo had tumor shrinkage, compared with 14% of those receiving chemotherapy, and 73% of Opdivo patients were alive after one year, compared with 42% in the group that received chemo. Immuno-oncology drugs could make chemotherapy obsolete in treating advanced melanoma, according to Georgina Long, associate professor at the Melanoma Institute Australia, who led the 418-patient study.